S

Choosing Appropriate Patients for Treatment With Monoclonal Antibody Therapy in Early-Relapsed MM

By Srinivas Devarakonda
482 views
December 6, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Recommended

17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views

·

7 months ago
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views

·

10 months ago
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

615 views

·

4 months ago
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

633 views

·

4 months ago
26:59

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

135 views

·

2 months ago
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

617 views

·

5 months ago
20:23

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

401 views

·

4 months ago
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

882 views

·

7 months ago
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

465 views

·

8 months ago
19:08

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

869 views

·

9 months ago
36:10

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

466 views

·

4 months ago
13:47

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

395 views

·

5 months ago
22:33

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

207 views

·

3 months ago
09:07

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

202 views

·

1 month ago
26:46

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

Samer Al Hadidi

599 views

·

7 months ago
05:35

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

Saurabh Chhabra

382 views

·

7 months ago
20:19

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - Multi…

Insights from 2023 ASCO® Annual Meeting

A. Paulus

1.8K views

·

1 year ago
03:42

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Moffitt Cancer Center

D. Hansen

375 views

·

7 months ago
35:37

2024 Updates on Multiple Myeloma Treatment

University of Colorado Division of Hematology

D. Sherbenou

430 views

·

7 months ago
16:55

New

Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th …

Springer Healthcare IME

S. Usmani

163 views

·

2 weeks ago
AUTOPLAY